Literature DB >> 30425069

Timing of treatment of smoldering myeloma: delay until progression.

Shaji K Kumar1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30425069      PMCID: PMC6234369          DOI: 10.1182/bloodadvances.2018021238

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


× No keyword cloud information.
  24 in total

1.  Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma.

Authors:  P R Greipp; R A Kyle
Journal:  Blood       Date:  1983-07       Impact factor: 22.113

2.  Smoldering multiple myeloma.

Authors:  R A Kyle; P R Greipp
Journal:  N Engl J Med       Date:  1980-06-12       Impact factor: 91.245

Review 3.  Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer.

Authors:  Eli Muchtar; Shaji K Kumar; Hila Magen; Morie A Gertz
Journal:  Leuk Lymphoma       Date:  2017-06-08

4.  Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

Authors:  María-Victoria Mateos; Miguel-Teodoro Hernández; Pilar Giraldo; Javier de la Rubia; Felipe de Arriba; Lucía López Corral; Laura Rosiñol; Bruno Paiva; Luis Palomera; Joan Bargay; Albert Oriol; Felipe Prosper; Javier López; Eduardo Olavarría; Nuria Quintana; José-Luis García; Joan Bladé; Juan-José Lahuerta; Jesús-F San Miguel
Journal:  N Engl J Med       Date:  2013-08-01       Impact factor: 91.245

5.  Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial.

Authors:  Ajay K Nooka; Michael Luhua Wang; Andrew J Yee; Jonathan L Kaufman; Jooeun Bae; Doris Peterkin; Paul G Richardson; Noopur S Raje
Journal:  JAMA Oncol       Date:  2018-12-13       Impact factor: 31.777

6.  Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Authors:  Clara Cesana; Catherine Klersy; Luciana Barbarano; Anna Maria Nosari; Monica Crugnola; Ester Pungolino; Livio Gargantini; Simonetta Granata; Marina Valentini; Enrica Morra
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

7.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

8.  New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.

Authors:  Ernesto Pérez-Persona; María-Belén Vidriales; Gema Mateo; Ramón García-Sanz; Maria-Victoria Mateos; Alfonso García de Coca; Josefina Galende; Guillermo Martín-Nuñez; José M Alonso; Natalia de Las Heras; José M Hernández; Alejandro Martín; Consuelo López-Berges; Alberto Orfao; Jesús F San Miguel
Journal:  Blood       Date:  2007-06-18       Impact factor: 22.113

9.  Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma.

Authors:  P Ravi; S Kumar; J T Larsen; W Gonsalves; F Buadi; M Q Lacy; R Go; A Dispenzieri; P Kapoor; J A Lust; D Dingli; Y Lin; S J Russell; N Leung; M A Gertz; R A Kyle; P L Bergsagel; S V Rajkumar
Journal:  Blood Cancer J       Date:  2016-07-29       Impact factor: 11.037

10.  Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.

Authors:  Arjun Lakshman; S Vincent Rajkumar; Francis K Buadi; Moritz Binder; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; David Dingli; Amie L Fonder; Suzanne R Hayman; Miriam A Hobbs; Wilson I Gonsalves; Yi Lisa Hwa; Prashant Kapoor; Nelson Leung; Ronald S Go; Yi Lin; Taxiarchis V Kourelis; Rahma Warsame; John A Lust; Stephen J Russell; Steven R Zeldenrust; Robert A Kyle; Shaji K Kumar
Journal:  Blood Cancer J       Date:  2018-06-12       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.